Environmental-mediated drug resistance: A target for multiple myeloma therapy

Expert Review of Hematology

Volumn 2, Issue 6, 2009, Pages 649-662

  Shain, Kenneth H ^a   Dalton, William S ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

CAM DR; Drug resistance; EM DR; Minimal residual disease; Multiple myeloma; Stromal cell

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA TOPOISOMERASE (ATP HYDROLYSING); FIBROBLAST GROWTH FACTOR; FLICE INHIBITORY PROTEIN; HYALURONIC ACID; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; JAGGED1; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAC1 PROTEIN; RAF PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR; SOMATOMEDIN; STAT PROTEIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BONE MARROW; CELL ADHESION; CYTOKINES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 77953437865     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.55     Document Type: Review

References (105)

1. Gertz MA. New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression. Leuk. Lymphoma 49(12), 2240-2245 (2008).
2. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J. Natl Compr. Cancer Netw. 5(2), 149-162 (2007).
3. Mitsiades CS, McMillin DW, Klippel S et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol. Oncol. Clin. North Am. 21(6), 1007-1034, vii-viii (2007).
4. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467-1473 (2006).
5. Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96(1), 355-357 (2000). (Pubitemid 30456493)
6. Martinelli G, Terragna C, Zamagni E et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 85(9), 930-934 (2000). (Pubitemid 30769839)
7. Fenk R, Ak M, Kobbe G et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 89(5), 557-566 (2004).
8. Bakkus MH, Bouko Y, Samson D et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br. J. Haematol. 126(5), 665-674 (2004).
9. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. J. Natl Cancer Inst. 101(2), 100-106 (2009).
10. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J. Clin. Oncol. 26(3), 480-492 (2008).
11. Van De Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92(10), 1399-1406 (2007).
12. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance. Curr. Opin. Oncol. 12(6), 557-563 (2000).
13. Alsayed Y, Ngo H, Runnels J et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109(7), 2708-2717 (2007).
14. Van De Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 19(12), 2177-2185 (2005).
15. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42(4), 669-680 (2008).
16. Lauring J, Abukhdeir AM, Konishi H et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 111(2), 856-864 (2008).
17. Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 20(6), 333-342 (2006).
18. Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 100(10), 3819-3821 (2002).
19. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. 7(8), 585-598 (2007).
20. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br. J. Haematol. 132(4), 385-397 (2006).
21. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5), 1761-1767 (2006).
22. Burns JM, Summers BC, Wang Y et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203(9), 2201-2213 (2006).
23. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1a modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/ fibronectin and VCAM-1. Blood 97(2), 346-351 (2001). (Pubitemid 32060316)
24. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24(27), 4462-4471 (2005).
25. Lu DY, Tang CH, Yeh WL et al. SDF-1a up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kBdependent pathway in microglia. Eur. J. Pharmacol. 613(1-3), 146-154 (2009).
26. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1-20 (2003).
27. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 18(11), 545-551 (2008).
28. Raza A, Reeves JA, Feldman EJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1), 86-93 (2008).
29. Feldman EJ, Cortes J, DeAngelo DJ et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22(9), 1707-1711 (2008).
30. Hausherr A, Tavares R, Schaffer M, Obermeier A, Miksch C, Mitina O et al. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene 26(34), 4987-4998 (2007).
31. Zoubeidi A, Rocha J, Zouanat FZ et al. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol. Cancer Res. 7(1), 142-155 (2009).
32. Pei XY, Dai Y, Tenorio S, Lu J et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 110(6), 2092-2101 (2007).
33. Burger R, Le Gouill S, Tai YT et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol. Cancer Ther. 8(1), 26-35 (2009).
34. Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev. Anticancer Ther. 9(3), 373-379 (2009).
35. Figlin RA, Brown E, Armstrong AJ et al. NCCN Task Force Report: MTOR inhibition in solid tumors. J. Natl Compr. Canc. Netw. 6(Suppl. 5), S1-S20 (2008).
36. Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 3(6), 639-647 (2007).
37. Younes H, Leleu X, Hatjiharissi E et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin. Cancer Res. 13(13), 3771-3775 (2007).
38. Hideshima T, Catley L, Raje N et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br. J. Haematol. 138(6), 783-791 (2007).
39. Campbell PJ, Green AR. The myeloproliferative disorders. N. Engl. J. Med. 355(23), 2452-2466 (2006).
40. Niu G, Wright KL, Ma Y, Wright GM et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25(17), 7432-7440 (2005).
41. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10(1), 48-54 (2004).
42. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41-51 (2007).
43. Shain KH, Yarde DN, Meads MB et al. b1 integrin adhesion enhances IL-6- mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69(3), 1009-1015 (2009).
44. Hallek M, Neumann C, Schaffer M et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp. Hematol. 25(13), 1367-1377 (1997).
45. Ishikawa H, Tsuyama N, Abroun S et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 99(6), 2172-2178 (2002).
46. Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J. Histochem. Cytochem.57(3), 239-247 (2009).
47. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14(9), 2519-2526 (2008).
48. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int. J. Biol. Markers (4), 218-222 (2006).
49. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br. J. Haematol. 138(4), 446-458 (2007).
50. Hehlgans S, Haase M, Cordes N. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775(1), 163-180 (2007).
51. Ohwada C, Nakaseko C, Koizumi M et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur. J. Haematol. 80(3), 245-250 (2008).
52. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 111(4), 2220-2229 (2008).
53. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93(5), 1658-1667 (1999).
54. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and g-irradiation. Leukemia 15(8), 1232-1239 (2001).
55. Hazlehurst LA, Valkov N, Wisner L et al. Reduction in drug-induced DNA double-strand breaks associated with b1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98(6), 1897-1903 (2001).
56. Hazlehurst LA, Argilagos RF, Dalton WS. b1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 136(2), 269-275 (2007).
57. Willis SN, Fletcher JI, Kaufmann T et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315(5813), 856-859 (2007).
58. Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II b levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochem. Pharmacol. 72(1), 11-18 (2006).
59. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via b1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19(38), 4319-4327 (2000).
60. Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1- associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110(5), 1631-1638 (2007).
61. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168(5), 2544-2553 (2002)
62. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103(9), 3503-3510 (2004).
63. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23(1), 10-24 (2009).
64. Matsui W, Wang Q, Barber JP et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68(1), 190-197 (2008).
65. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-a (MIP-1 a) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101(9), 3568-3573 (2003).
66. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17(6), 1175-1182 (2003).
67. Gatenby RA. A change of strategy in the war on cancer. Nature 459(7246), 508-509 (2009).
68. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 14(Suppl. 1), 35-48 (2005).
69. Hazlehurst LA, Enkemann SA, Beam CA et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63(22), 7900-7906 (2003).
70. Nakagawa Y, Abe S, Kurata M et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am. J. Hematol. 81(11), 824-831 (2006).
71. Knobloch J, Reimann K, Klotz LO, Ruther U. Thalidomide resistance is based on the capacity of the glutathionedependent antioxidant defense. Mol. Pharm. 5(6), 1138-1144 (2008).
72. Oerlemans R, Franke NE, Assaraf YG et al. Molecular basis of bortezomib resistance: proteasome subunit b5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6), 2489-2499 (2008).
73. Franke NE, Kaspses GL, van de Berg N et al. Aquired resistance to bortezomib in human RPMI 8226 mutliple myeloma cells: Molecular characterization, cross-resistance with other proteosome inhibitors but marked sensitization to glucocorticoids. Blood ASH Annual Meeting Abstract 2008 December 112, 2640 (2008).
74. Ling S, NikolicAM, Al-Shabeeb A. Characterization of bortezomib resistance in multiple myeloma cell lines. Blood ASH Annual Meeting Abstract 112, 2639 (2008).
75. Sanchez-Vega B, Gandhi V. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br. J. Haematol. 144(6), 856-864 (2009).
76. Greenstein S, Krett NL, Kurosawa Y et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp. Hematol. 31(4), 271-282 (2003).
77. Kim H, Rafiuddin-Shah M, Tu HC et al. Hierarchical regulation of mitochondriondependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8(12), 1348-1358 (2006).
78. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015- 070) in multiple myeloma. Blood 109(12), 5430-5438 (2007).
79. Chauhan D, Velankar M, Brahmandam M et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26(16), 2374-2380 (2007).
80. Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 218(2), 127-139 (2005).
81. Vangsted A, Gimsing P, Klausen TW et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int. J. Cancer 120(5), 1036-1045 (2007).
82. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106(2), 698-705 (2005).
83. Mitsiades N, Mitsiades CS, Poulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99(22), 14374-14379 (2002).
84. Prince HM, Honemann D, Spencer A et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A Phase 2 study of pazopanib (GW786034). Blood 113(19), 4819-4820 (2009).
85. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1), 105-115 (1999).
86. Tassone P, Neri P, Burger R et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin. Cancer Res. 11(11), 4251-4258 (2005).
87. Rossi JF, Manges RF, Sutherland HJ et al. Preliminary results of CNTO 328, an anti-IL-6 monoclonal antibody, in combination with bortezomib in the treatment of replapsed or refractory multiple myeloma. Blood ASH Annual Meeting Abstract 112, 867 (2008).
88. Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22(6), 1095-1102 (2004).
89. Azab AK, Azab F, Blotta S et al. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114(3), 619-629 (2009).
90. Tavor S, Eisenbach M, Jacob-Hirsch J et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22(12), 2151-5158 (2008).
91. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin. Cancer Res. 14(24), 7975-7980 (2008).
92. Bisping G, Wenning D, Kropff M et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin. Cancer Res. 15(2), 520-531 (2009).
93. Matsunaga T, Takemoto N, Sato T et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9(9), 1158-1165 (2003).
94. Ricart AD, Tolcher AW, Liu G et al. Volociximab, a chimeric monoclonal antibody that specifically binds a5b1 integrin: A Phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14(23), 7924-7929 (2008).
95. Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind avb3, avb5, and a5b1 integrins with low-nanomolar affinity. Proteins 77(2), 359-369 (2009).
96. Nair RR, Emmons MF, Cress AE et al. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol. Cancer Ther. 8(8), 2441-2451 (2009).
97. Pedranzini L, Dechow T, Berishaj M et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 66(19), 9714-9721 (2006).
98. Coluccia AM, Cirulli T, Neri P et al. Validation of PDGFRb and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112(4), 1346-1356 (2008).
99. Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk. Lymphoma 50(1), 137-140 (2009).
100. Barlogie B, Anaissie E, Van Rhee F et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 138(2), 176-185 (2007).
101. Barlogie B, Van Rhee F, Shaughnessy JD Jr, Anaissie E, Crowley J. Making progress in treating multiple myeloma with total therapies: Issue of complete remission and more. Leukemia 22(8), 1633-1636 (2008).
102. Shaughnessy JD Jr, Haessler J et al. An update on the role of thalidomide (THAL) in total therapy 2 (TT2) for newly diagnosed patients with multiple myeloma (MM): Analysis of subgroups defined by standard prognostic factors (SPF) and gene expression profiling (GEP)-derived subgroups. ASH Annual Meeting Abstracts November 16,108(11), 3389 (2006).
103. Matsunaga T, Takemoto N, Sato T et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 1158-1165 (2003).
104. Ricart AD, Tolcher AW, Liu G et al. Volociximab, a chimeric monoclonal antibody that specifically binds a5b1 integrin: A Phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14, 7924-7929 (2008).
105. Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind avb3, avb5, and a5b1 integrins with low-nanomolar affinity. Proteins 77(2), 359-369 (2009).